27 Sept 2022listing compliance notice▼ BadMajor
Arcadia again fell below Nasdaq's $1.00 minimum bid price requirement, echoing the same deficiency first flagged in 2017.
Announcements, explained
Each one in plain English, with the numbers worked through for a shareholder.
18 Aug 2022director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Marketing Officer Laura Pitlik received a stock option grant for 23,000 shares.
18 Aug 2022director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Financial Officer Pamela Haley received a stock option grant for 23,000 shares.
16 Aug 2022securities registration● Neutral
Arcadia Biosciences, Inc. filed a prospectus supplement for an offering off its existing shelf.
16 Aug 2022capital raising announcement▼ BadMajor
Arcadia raised capital via a registered direct offering at $1.05876/share (4,722,506 shares or pre-funded warrants), with separately-priced long-dated investment options -- pricing now hovering near the $1.00 level that periodically triggers Nasdaq bid-price deficiencies.
11 Aug 2022quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $3.9 million and a net loss of $3.8 million for the period ended 2022-06-30.
11 Aug 2022quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $3.9 million and a net loss of $3.8 million for the period ended 2022-06-30.
3 Aug 2022director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Financial Officer Pamela Haley bought 700 shares on the open market at $0.70.
3 June 2022director interest notice● Neutral
Arcadia Biosciences, Inc. director Amy Yoder received a stock option grant for 23,620 shares.
3 June 2022director interest notice● Neutral
Arcadia Biosciences, Inc. director Kevin Comcowich received a stock option grant for 55,114 shares.
3 June 2022director interest notice● Neutral
Arcadia Biosciences, Inc. director Gregory D Waller received a stock option grant for 23,620 shares.
3 June 2022director interest notice● Neutral
Arcadia Biosciences, Inc. director Albert D. Bolles received a stock option grant for 23,620 shares.
3 June 2022director interest notice● Neutral
Arcadia Biosciences, Inc. director Deborah D Carosella received a stock option grant for 23,620 shares.
3 June 2022director interest notice● Neutral
Arcadia Biosciences, Inc. director Lilian Shackelford Murray received a stock option grant for 23,620 shares.
12 May 2022quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $3.2 million and a net loss of $4.5 million for the period ended 2022-03-31.
12 May 2022quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $3.2 million and a net loss of $4.5 million for the period ended 2022-03-31.
21 Apr 2022securities registration● Neutral
Arcadia Biosciences, Inc. registered a securities offering with the SEC using its shelf eligibility.
13 Apr 2022director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Financial Officer Pamela Haley received a stock option grant for 88,000 shares.
13 Apr 2022director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Marketing Officer Laura Pitlik received a stock option grant for 54,000 shares.
11 Feb 2022securities registration● Neutral
Arcadia Biosciences, Inc. filed the final prospectus for a registered offering.
11 Feb 2022substantial holder notice● Neutral
Mitchell P. Kopin, Daniel B. Asher, Intracoastal Capital LLC reported a Arcadia Biosciences, Inc. shareholding of 1,058,559 shares (4.60% of votes) in a periodic institutional filing.
4 Feb 2022director interest notice● Neutral
Stanley Jacot Jr. became a Arcadia Biosciences, Inc. Chief Executive Officer and company insider (initial ownership filing).
4 Feb 2022substantial holder notice● Neutral
Hudson Bay Capital Management LP, Sander Gerber reported a Arcadia Biosciences, Inc. shareholding of 890,049 shares (3.86% of votes) in a periodic institutional filing.
4 Feb 2022director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Executive Officer Stanley Jacot Jr. received a stock option grant for 316,108 shares.
28 Jan 2022securities registration● Neutral
Arcadia Biosciences, Inc. registered a securities offering with the SEC.
15 Nov 2021quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $2.4 million and a net loss of $2.2 million for the period ended 2021-09-30.
15 Nov 2021quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $2.4 million and a net loss of $2.2 million for the period ended 2021-09-30.
16 Aug 2021quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $1.4 million and a net loss of $5.3 million for the period ended 2021-06-30.
16 Aug 2021quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $1.4 million and a net loss of $5.3 million for the period ended 2021-06-30.
13 July 2021director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Marketing Officer Laura Pitlik received a stock option grant for 75,000 shares.